AbbVie Beats on Q3 Growth, Wins Skyrizi Crohn's Approval and Lutikizumab Phase 3
ABBV sits 55% above its 52-week low of $190.75.
Summary
AbbVie posted Q3 2026 revenue of $17.404 billion, up 10.3% year over year, with adjusted EPS of $3.82, and lifted full-year adjusted EPS guidance to $13.95-$13.99. Skyrizi brought in $5.78 billion and Rinvoq $2.71 billion, while neuroscience contributed $3.39 billion; Humira fell 31.2% but the rest of the portfolio more than covered it. The FDA approved Skyrizi for subcutaneous induction in moderate-to-severe Crohn's disease, and AbbVie has filed the same use with the EMA. Lutikizumab hit its primary endpoint in the Phase 3 INTREPID trial in hidradenitis suppurativa, with data presentation planned and possible regulatory submissions in the second half of 2027. The stock is trading near its 52-week high, so the bar was high; the guidance raise plus two pipeline wins give the quarter a solid read-through.
At the time of this announcement, ABBV was trading at $295.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $521.1B. The 52-week trading range was $190.75 to $298.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.